Canada's Health Regulator First to OK Kevzara Drug by Sanofi, Regeneron
February 01 2017 - 2:37AM
Dow Jones News
By Inti Landauro
PARIS--Health Canada, the country's health regulator, is the
first regulator to authorize Kevzara, also known sarilumab, a new
treatment for moderately to severely active rheumatoid arthritis
made by French drug giant Sanofi S.A. (SAN.FR) and its partner
Regeneron Pharmaceuticals Inc. (REGN), the companies said
Wednesday.
The new drug is designed to treat adult patients who suffer from
moderately active rheumatoid arthritis who have had an inadequate
response to or intolerance of biologic or nonbiologic
disease-modifying antirheumatic drugs.
The companies expect the European regulator to make a decision
on allowing marketing of the drug in the European Union this year
and the U.S. Food and Drug Administration to make a decision in the
second quarter.
Large pharmaceuticals like Sanofi are scrambling to get new
drugs on the market to replace several best-sellers whose patents
entered or are soon entering public domain.
Separately, Sanofi said Wednesday that the FDA approved the
marketing of Xyzal Allergy 24HR over the counter in the U.S.
-Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
February 01, 2017 02:22 ET (07:22 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
